C. Ola Landgren, MD, PhD, professors of medicine and chief of the Myeloma Service at Memorial Sloan Kettering Cancer Center spoke with the American Journal of Managed Care about MRD. He said while it's been a topic of research for many years, recently it's become more important than ever in treating cancer. "Minimal residual disease is a topic that is on everybody's lips these days. You cannot attend one single meeting without hearing about the minimal residual disease [MRD] testing in myeloma and other diseases, as well," he said.
To read a full transcript of his interview, visit AJMC's website.